Basic Information
| LncRNA/CircRNA Name | TUG1 |
| Synonyms | NA |
| Region | GRCh38_22:30969245-30979395 |
| Ensemble | ENSG00000253352 |
| Refseq | NR_002323 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR |
| Sample | Prostatic stromal immortalized cell line WPMY-1 and PCa cell lines (LNCap, DU145, PC-3 and CWR22Rv1), blood |
| Expression Pattern | up-regulated |
| Function Description | QRT-PCR data revealed a higher plasma level of TUG1 in PCa patients than in those of healthy controls. In particular, PCa patients with stage III+IV had a higher level of TUG1 relative to those with stage I+II. Moreover, the TUG1 level was higher in PCa patients with a higher PSA level (??10 ng/mL), Gleason grading (??7) or TNM stage (N1, M1). There was no significant correlation between the plasma level of TUG1 and the age of PCa patients. The ROC and Kaplan-Meier curves indicated the diagnostic and prognostic values of TUG1 in PCa. The overexpression of TUG1 markedly accelerated PCa cells to proliferate and migrate. |
| Pubmed ID | 31210308 |
| Year | 2019 |
| Title | LncRNA TUG1 aggravates the progression of prostate cancer and predicts the poor prognosis |
External Links
| Links for TUG1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |